Shu-Fen Coker

Shu-Fen Coker has a diverse work experience spanning over two decades. Shu-Fen began their career as a Postdoctoral Research Fellow at the University of Southampton in 1998, where they worked until 2005.

In 2008, Shu-Fen joined the UCL Department of Medicine as a Visiting Fellow. Their research focused on human patatin-like phospholipase domain containing 3 (PNPLA3) and human heart succinyl-CoA:3-ketoacid coenzyme A transferase (SCOT). Shu-Fen performed high-throughput cloning and expression, identified expressible constructs, and performed expression conditions.

In 2014, they joined UCB as a Research Scientist. Shu-Fen worked on therapeutic antibodies and their target Keap1. Their responsibilities included high-throughput transient expression of antibody constructs and cloning and expression of Keap1.

Shu-Fen then joined Recombinant Antibody Technology in 2016 as a Research and Development Scientist. Here, they focused on therapeutic antibodies and was involved in expression, purification, and characterization of recombinant single domain antibodies. Shu-Fen also determined the binding characteristics of the purified samples.

From 2017 to 2021, Shu-Fen worked at Ipsen as an Associate Scientist. During their tenure, they contributed significantly to various projects, including engineering and production of recombinant BoNTs and design and production of enzymes with increased catalytic activity. Shu-Fen also developed higher-throughput expression and purification platforms, designed an UPLC-based enzyme assay, and created a tool molecule for imaging and binding assays.

Currently, Shu-Fen is employed at Ossianix as a Senior Scientist. Their role involves structural modeling and engineering of shark antibodies and the development and implementation of a higher-throughput protein purification and quality control process.

From 1994 to 1997, Shu-Fen Coker attended the University of Leeds and obtained a PhD in Biochemistry.